Preemptive Pharmacogenomics Testing Among Geriatric Patients

Completed · Not applicable

Conditions studied: Polypharmacy, Pharmacogenomic Testing

In brief

The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, and costs of care.

Key facts

Study ID

NCT05091879

Run by

Geisinger Clinic

People needed

66

Starts

2023-03-28

Expected to finish

2026-06-01

Last updated by the study team

2026-06-15

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Follows at a Geisinger 65 Forward clinic location
• Active prescriptions for 5 or more medications

You may not qualify if…

• Liver transplantation
• Allogenic hematopoetic stem cell transplantation
• Previously enrolled in the Electronic Medical Records and Genomics (eMERGE) pharmacogenomics cohort

Where it is running

• Geisinger — Danville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.